Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539743 | 0.84 | PPARD (0.38) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL6539599 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2PPARD | |
| SCHEMBL6539133 | 0.82 | PTGS2 (0.43) | HDAC6PPARD | |
| SCHEMBL6538981 | 0.82 | MAOB (0.54) | ALDH1A1SMN1; SMN2HDAC6PPARD | |
| SCHEMBL6540424 | 0.78 | ALDH1A1 (0.42) | ALDH1A1POLBMTNR1APPARD | |
| SCHEMBL6539090 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CNR2HDAC6PPARD | |
| SCHEMBL2093102 | 0.76 | CA12 (0.73) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL6539285 | 0.76 | L3MBTL1 (0.47) | ALDH1A1SMN1; SMN2PPARD | |
| SCHEMBL6539732 | 0.75 | ADRA1D (0.45) | ALDH1A1 | |
| SCHEMBL6230071 | 0.75 | ESR2 (0.47) | ALDH1A1POLBPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | CA12 3116/4885CA1 1632/4885CA2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.